January 30, 2020 - "2019 – a record year further establishing a strong foundation for future growth"
JANUARY 30, 2020 – In 2019 we delivered the strongest financial results, with Q4 being no exception. The development was driven YoY increased net revenues for Zubsolv and strong cost control. Operationally, we signed two partnership agreements with GAIA to develop digital therapeutics for the treatment of Opioid and Alcohol Use Disorder and we made pipeline progresses. With a solid cash position we will continue to deliver our strategy for future growth with the aim to build an even more exciting future.
JANUARY 29, 2020 - The PK study for OX338, evaluating novel formulations of ketorolac for the treatment of pain showed promising results. The formulations demonstrated improved bioavailability and tolerability compared to the commercially available reference product. The next step is to further optimise the formulation to ensure obtaining a unique product profile and strong IP protection.
Investors, analysts and media are invited to attend our Capital Markets Day that will take place at, Helio GT 30, Grev Turegatan 30, Stockholm, Sweden. The program will start at 1:30 pm CET, with registration from 1:00 pm CET. The event plans to end at 4.00 pm CET. A formal invitation with a complete program will be sent out at a later date. #strategy #pipeline #digitalhealth
OUR EMPLOYEES ARE KEY TO OUR SUCCESS. Proud to have our first global intranet launched with the ultimate aim to con… https://t.co/KGcuwafz71
Tullen: "Sverige har en opioidepidemi". 2019 beslagstogs dubbelt så mycket av den syntetiska opioiden tramadol i Sv… https://t.co/J4YH9dP41S